PE20070183A1 - Anticuerpos monoclonales anti-trkb - Google Patents
Anticuerpos monoclonales anti-trkbInfo
- Publication number
- PE20070183A1 PE20070183A1 PE2006000611A PE2006000611A PE20070183A1 PE 20070183 A1 PE20070183 A1 PE 20070183A1 PE 2006000611 A PE2006000611 A PE 2006000611A PE 2006000611 A PE2006000611 A PE 2006000611A PE 20070183 A1 PE20070183 A1 PE 20070183A1
- Authority
- PE
- Peru
- Prior art keywords
- trkb
- seq
- human
- monoclonal antibodies
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
SE REFIERE A ANTICUERPOS MONOCLONALES PARA EL TrkB HUMANO, CARACATERIZADO PORQUE UNE UNO O AMBOS DE LOS EPITOPOS DE TRKB HUMANO CON LAS SECUENCIAS KNEYGKD (SEQ. ID.No.7) Y KGNPKP (SEQ. ID.No.8), ENLVGED (SEQ. ID.No.10) Y OPCIONALMENTE CON LA SECUENCIA AGDPVP (SEQ. ID.No.11), Y SE PRODUCE A PARTIR DEL HIBRIDOMA DEPOSITADO EN EL ATCC CON DEPOSITO PTA-6948 O DE UNA CELULA MADRE DEL MISMO. ESTE ANTICUERPO ES SELECTIVO PARA PARA EL TrkB HUMANO EN QUE NO UNEN (O ACTIVAN) EL TrkA HUMANO O EL TrkC HUMANO, Y PUEDEN PRESENTAR REACTIVIDAD CRUZADA TrkB MURINA. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS Y METODOS DE PREPARACION DE DICHOS ANTICUERPOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68770505P | 2005-06-06 | 2005-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070183A1 true PE20070183A1 (es) | 2007-02-26 |
Family
ID=37400063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000611A PE20070183A1 (es) | 2005-06-06 | 2006-06-05 | Anticuerpos monoclonales anti-trkb |
Country Status (21)
Country | Link |
---|---|
US (2) | US7750122B2 (es) |
EP (2) | EP1891114A2 (es) |
JP (1) | JP2008545781A (es) |
KR (1) | KR20080032070A (es) |
CN (1) | CN101273064A (es) |
AR (1) | AR053401A1 (es) |
AU (1) | AU2006255101A1 (es) |
BR (1) | BRPI0610938A2 (es) |
CA (1) | CA2610771A1 (es) |
EC (1) | ECSP077978A (es) |
GT (1) | GT200600240A (es) |
IL (1) | IL187710A0 (es) |
MX (1) | MX2007015292A (es) |
NI (1) | NI200700315A (es) |
NO (1) | NO20076157L (es) |
NZ (1) | NZ563941A (es) |
PA (1) | PA8678401A1 (es) |
PE (1) | PE20070183A1 (es) |
RU (1) | RU2007144678A (es) |
TW (1) | TW200722437A (es) |
WO (1) | WO2006133164A2 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PT2248899E (pt) | 2003-03-19 | 2015-09-23 | Biogen Ma Inc | Proteína de ligação do receptor nogo |
ES2395094T3 (es) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Tratamiento de afecciones que implican la desmielinización |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
CN101573381A (zh) * | 2006-11-09 | 2009-11-04 | Irm责任有限公司 | 激动剂TrkB抗体及其用途 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
JP2010513461A (ja) * | 2006-12-20 | 2010-04-30 | ライナット ニューロサイエンス コーポレイション | 自己免疫障害を治療するためのTrkBアゴニスト |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
JP5674469B2 (ja) * | 2007-10-11 | 2015-02-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | LINGO−1アンタゴニストおよびTrkBアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
US20100297115A1 (en) * | 2007-10-23 | 2010-11-25 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
CN101918540B (zh) * | 2007-11-08 | 2016-05-11 | 比奥根Ma公司 | Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用 |
DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
AU2010243551B2 (en) * | 2009-04-30 | 2015-03-26 | Ablynx Nv | Method for the production of domain antibodies |
WO2011103667A1 (en) * | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
GB2491106A (en) * | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
CN102645542A (zh) * | 2012-04-20 | 2012-08-22 | 苏州大学 | Bdnf酶联免疫测定试剂盒 |
WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
AU2013337264B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
CN102901815B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法 |
CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
JP6868394B2 (ja) | 2014-05-16 | 2021-05-12 | ファイザー・インク | 二重特異性抗体 |
MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
US10975152B2 (en) * | 2016-05-03 | 2021-04-13 | The Scripps Research Institute | TrkB agonist antibodies and methods for treating an ocular degenerative disorder characterized by degeneration of retinal ganglion cells (RGCs) |
US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
EP4095161A1 (en) * | 2017-03-15 | 2022-11-30 | Tsinghua University | Novel anti-trkb antibodies |
US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
CA3083452A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
CN110028585A (zh) * | 2019-02-18 | 2019-07-19 | 广东三九脑科医院 | 兔抗人trk蛋白单克隆抗体制备及其免疫组化用途 |
WO2021102276A1 (en) | 2019-11-22 | 2021-05-27 | Ossianix, Inc. | Bbb-shuttling-vnars conjugated to neurotrophic agonist antibodies to treat neurodegenerative diseases and conditions |
US20230103618A1 (en) * | 2020-01-30 | 2023-04-06 | Fred Hutchinson Cancer Center | Antibody-based compositions for targeting tropomyosin receptor kinase b (trkb) isoforms |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5817471A (en) * | 1991-03-14 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
ZA922947B (en) * | 1991-04-23 | 1993-01-27 | Regeneron Pharma | Assay systems for neurotrophin activity |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5625121A (en) * | 1993-09-02 | 1997-04-29 | Bristol-Myers Squibb Company | Mice deficient in nerve growth factor receptors encoded by trkB |
US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
US5844092A (en) * | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US20040058416A1 (en) * | 1994-03-18 | 2004-03-25 | Presta Leonard G. | Human trk receptors and neurotrophic factor inhibitors |
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5601820A (en) * | 1994-07-07 | 1997-02-11 | Children's Hospital Of Philadelphia | Compositions and methods of making and using human full length TRK-B |
US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5688911A (en) * | 1995-05-03 | 1997-11-18 | Schneider; Rainer | Trk neurotrophin binding motifs |
US5880153A (en) * | 1995-11-13 | 1999-03-09 | Spinal Cord Society | Method for upregulation of TRKB and TRKC receptors in central nervous system neurons |
JPH10212241A (ja) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Bdnfを安定に含有する製剤 |
CA2259163C (en) | 1996-07-19 | 2004-07-06 | Amgen Inc. | Nt-3 and bdnf analogs having improved circulating life and/or absorption |
WO2001064742A1 (fr) | 2000-02-29 | 2001-09-07 | Sumitomo Pharmaceuticals Company, Limited | Bdnf modifie |
ATE446366T1 (de) * | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
US20020169154A1 (en) * | 2001-04-04 | 2002-11-14 | Cephalon, Inc. | Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents |
US20060148749A1 (en) * | 2002-02-22 | 2006-07-06 | University Of Maryland | Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
US20040186044A1 (en) * | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
-
2006
- 2006-06-05 MX MX2007015292A patent/MX2007015292A/es active IP Right Grant
- 2006-06-05 RU RU2007144678/13A patent/RU2007144678A/ru unknown
- 2006-06-05 PE PE2006000611A patent/PE20070183A1/es not_active Application Discontinuation
- 2006-06-05 US US11/446,875 patent/US7750122B2/en not_active Expired - Fee Related
- 2006-06-05 EP EP06772254A patent/EP1891114A2/en not_active Ceased
- 2006-06-05 GT GT200600240A patent/GT200600240A/es unknown
- 2006-06-05 WO PCT/US2006/021878 patent/WO2006133164A2/en active Application Filing
- 2006-06-05 EP EP10179506A patent/EP2298813A3/en not_active Withdrawn
- 2006-06-05 CN CNA2006800287787A patent/CN101273064A/zh active Pending
- 2006-06-05 NZ NZ563941A patent/NZ563941A/en not_active IP Right Cessation
- 2006-06-05 AU AU2006255101A patent/AU2006255101A1/en not_active Abandoned
- 2006-06-05 TW TW095119800A patent/TW200722437A/zh unknown
- 2006-06-05 KR KR1020087000331A patent/KR20080032070A/ko not_active Application Discontinuation
- 2006-06-05 AR ARP060102341A patent/AR053401A1/es not_active Application Discontinuation
- 2006-06-05 CA CA002610771A patent/CA2610771A1/en not_active Abandoned
- 2006-06-05 PA PA20068678401A patent/PA8678401A1/es unknown
- 2006-06-05 BR BRPI0610938-1A patent/BRPI0610938A2/pt not_active IP Right Cessation
- 2006-06-05 JP JP2008515819A patent/JP2008545781A/ja active Pending
-
2007
- 2007-11-28 IL IL187710A patent/IL187710A0/en unknown
- 2007-11-28 NO NO20076157A patent/NO20076157L/no not_active Application Discontinuation
- 2007-12-03 EC EC2007007978A patent/ECSP077978A/es unknown
- 2007-12-03 NI NI200700315A patent/NI200700315A/es unknown
-
2010
- 2010-06-30 US US12/827,321 patent/US20110150893A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20076157L (no) | 2008-02-07 |
WO2006133164A2 (en) | 2006-12-14 |
GT200600240A (es) | 2007-03-14 |
TW200722437A (en) | 2007-06-16 |
EP2298813A3 (en) | 2012-03-21 |
PA8678401A1 (es) | 2009-05-15 |
ECSP077978A (es) | 2008-01-23 |
NI200700315A (es) | 2008-07-03 |
US20070059304A1 (en) | 2007-03-15 |
AU2006255101A1 (en) | 2006-12-14 |
KR20080032070A (ko) | 2008-04-14 |
EP1891114A2 (en) | 2008-02-27 |
RU2007144678A (ru) | 2009-07-20 |
EP2298813A2 (en) | 2011-03-23 |
US7750122B2 (en) | 2010-07-06 |
US20110150893A1 (en) | 2011-06-23 |
WO2006133164A3 (en) | 2007-03-15 |
IL187710A0 (en) | 2008-08-07 |
CN101273064A (zh) | 2008-09-24 |
BRPI0610938A2 (pt) | 2010-08-03 |
NZ563941A (en) | 2011-09-30 |
MX2007015292A (es) | 2008-02-21 |
JP2008545781A (ja) | 2008-12-18 |
CA2610771A1 (en) | 2006-12-14 |
AR053401A1 (es) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070183A1 (es) | Anticuerpos monoclonales anti-trkb | |
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
RU2011134500A (ru) | Антитела и иммуноконъюгаты и их применения | |
AR107902A2 (es) | Anticuerpos anti-cd37 | |
RU2005132389A (ru) | Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами | |
ES2570153T3 (es) | Anticuerpos anti-C5aR con propiedades mejoradas | |
NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
RU2014120154A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
ES2628108T3 (es) | Anticuerpos multiespecíficos | |
RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
RS52452B (en) | Antibodies and Immunoconjugates and Their Use | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
PE20061323A1 (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
NZ605980A (en) | Anti-fap antibodies and methods of use | |
RS54624B1 (en) | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 | |
RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |